USP502

USP502 is an early-stage research asset developed by Uscare Pharm, a South Korean biotechnology firm specializing in regenerative medicine. It is categorized within the company's "Product Innovation" pipeline, which focuses on translating proprietary material innovations into therapeutic applications. The primary indication for USP502 is tissue regeneration. While specific molecular details have not been publicly disclosed, the program likely leverages Uscare Pharm's core expertise in regenerative materials such as polydeoxyribonucleotide (PDRN), polynucleotide (PN), or exosomes to facilitate cellular repair and wound healing. As of 2024, the program remains in the early research phase.